Odyssey Therapeutics, Inc. stock analysis
Odyssey Therapeutics, Inc. (ODTX) Stock Price & Analysis
ODTX Stock Chart & Stats
- Day’s Range
- $18.46 - $19.76
- 52-Week Range
- $15.10 - $29.05
- Previous Close
- $20.10
- Volume
- N/A
- Average Volume (3M)
- 304.70K
- Market Cap
- $920.02M
- Enterprise Value
- $762.72M
- Total Cash (Recent Filing)
- $326.00M
- Total Debt (Recent Filing)
- $23.48M
- Price to Earnings (P/E)
- ―
- Beta
- 0.02
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Odyssey Therapeutics, Inc. News
Odyssey Therapeutics publishes regulatory T-cell data in Journal of Immunology
Odyssey Therapeutics (ODTX) announced the publication of a research paper titled “TNFR2 agonism increases tissue and effector Treg cells” in The Journal of Immunology. The findings demonstrate that tumor necrosis
Odyssey Therapeutics Advances Early OD-001 Study as Investors Watch for Drug Development Signals
Odyssey Therapeutics, Inc. ($ODTX) announced an update on their ongoing clinical study. Study Overview: Odyssey Therapeutics, Inc. is evaluating how the investigational drug OD-001 moves through the body in healthy
Odyssey Therapeutics reports OD-001 trial meets primary endpoint
Odyssey Therapeutics (ODTX) announced results from the completed induction period of its Phase 2a clinical trial evaluating OD-001, an oral, selective RIPK2 scaffolding inhibitor, in patients with moderate-to-severe ulcerative colitis,
Tyler Van Buren Initiates Buy on Odyssey Therapeutics Citing Strong OD-001 Phase IIa Data, Novel RIPK2 Mechanism, and Emerging Pipeline Optionality
TD Cowen analyst Tyler Van Buren has maintained their bullish stance on ODTX stock, giving a Buy rating today. Tyler Van Buren has given his Buy rating due to a
ODTX FAQ
What was Odyssey Therapeutics, Inc.’s price range in the past 12 months?
What is Odyssey Therapeutics, Inc.’s market cap?
When is Odyssey Therapeutics, Inc.’s upcoming earnings report date?
How were Odyssey Therapeutics, Inc.’s earnings last quarter?
Is Odyssey Therapeutics, Inc. overvalued?
Does Odyssey Therapeutics, Inc. pay dividends?
What is Odyssey Therapeutics, Inc.’s EPS estimate?
How many shares outstanding does Odyssey Therapeutics, Inc. have?
What happened to Odyssey Therapeutics, Inc.’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Odyssey Therapeutics, Inc.?
What is the TipRanks Smart Score and how is it calculated?
Odyssey Therapeutics, Inc. Stock Smart Score
Company Description
Odyssey Therapeutics, Inc.
Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on discovering and developing novel treatments for autoimmune and inflammatory diseases. Its diverse pipeline features several key drug candidates: OD-001, an oral small molecule that inhibits receptor-interacting protein kinase 2, which is currently in Phase 2a clinical trials for ulcerative colitis. Also included is OD-002, an oral small molecule SLC15A4 inhibitor engineered to prevent harmful inflammatory responses driven by TLR7/8/9-mediated activation of interferon regulatory factor 5 (IRF5). Another program, OD-003, is a protein therapeutic designed to selectively agonize tumor necrosis factor receptor 2 on T regulatory cells. Further assets in its portfolio comprise a bispecific antagonist targeting TSLP and IL-33, an oral small molecule functioning as an interleukin-1 receptor-associated kinase 4 scaffolding inhibitor, and a separate small molecule inhibitor specifically targeting IRF5. The company was founded in 2021 and is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Gary D. Glick
- Employees
- 100
- Website
- odysseytx.com
- Address
- 51 Sleeper Street, Boston, MA, 02210, US
Odyssey Therapeutics, Inc. (ODTX) Earnings & Revenues
ODTX Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 1 | 6 | 13 |
| Technical Analysis | 1 | 6 | 3 |
| Moving Averages | 0 | 0 | 10 |











